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Spinal muscular atrophy (SMA) is the leading genetic cause of death in childhood. Spinraza 
(nusinersen) is the first marketed therapy for SMA, approved in the USA in December 2016 
and in Europe in June 2017. To highlight the approval of Spinraza, Gene Therapy is 
publishing a special issue on Spinraza and Advanced Therapies. The purpose of the current 
compilation is to provide a set of online materials of relevance to the special issue. The 
weblinks include resources from governments, charitable associations, scientific societies 
and commercial information providers. The list is not exhaustive but rather aims to provide a 
starting point to navigate this field. 
 
• Nusinersen mechanism (Youreka Science in YouTube): 
https://www.youtube.com/watch?v=wrN-BRrzZ5E  
• NIH Genetics Home Reference database entry on SMA: 
https://ghr.nlm.nih.gov/condition/spinal-muscular-atrophy#  
• Online Inheritance in Man (OMIM) database entry on type I SMA: 
https://www.omim.org/entry/253300 
• ClinicalTrials.gov search for SMA: 
https://clinicaltrials.gov/ct2/results?cond=spinal+muscular+atrophy&term=&cntry1=&s
tate1=&SearchAll=Search+all+studies&recrs 
• U. S. Food & Drug Administration (FDA) Vaccines, Blood and Biologics section: 
https://www.fda.gov/BiologicsBloodVaccines/default.htm  
• European Medicines Agency (EMA) Advanced Therapy Medicinal Products (ATMPs): 
http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_con
tent_000294.jsp  
• China Food and Drug Administration (SFDA): http://eng.sfda.gov.cn/WS03/CL0755  
• SMA News Today: https://smanewstoday.com  
• Cure SMA (USA): http://www.curesma.org  
• SMA Foundation (USA): http://www.smafoundation.org  
• SMA Europe: http://www.sma-europe.eu  
• SMA Support UK: http://www.smasupportuk.org.uk  
• The SMA Trust (UK): http://www.smatrust.org  
• Association Française contre les Myopathies (AFM, France): http://www.afm-
telethon.fr  
• Deutsche Gesellschaft fuer Muskelkranke/Initiative SMA (DGM, Germany): 
http://www.initiative-sma.de  
• Famiglie SMA (Italy): http://www.famigliesma.org  
• Fundacja SMA (Poland): http://www.fsma.pl  
• Prinses Beatrix Spierfonds (Netherlands): https://prinsesbeatrixspierfonds.nl 
• Vereniging Spierziekten Nederland (VSN, Netherlands): http://www.spierziekten.nl  
• Fundación AME (FundAME, Spain): http://www.fundame.net  
• Familias AME Argentina: http://www.fameargentina.com.ar 
• SMA Australia: https://smaaustralia.org.au  
• Families of SMA Hong Kong: http://www.fsma.org.hk  
• Children with SMA (Ukraine): http://www.csma.org.ua  
• Genetic Alliance (USA): http://www.geneticalliance.org  
• Rare Diseases Europe (EURORDIS): http://www.eurordis.org  
• Genetic Alliance UK: https://www.geneticalliance.org.uk  
• Findacure: http://www.findacure.org.uk  
• American Society for Gene and Cell Therapy (ASGCT): http://www.asgct.org  
• European Society for Gene and Cell Therapy (ESGCT): https://www.esgct.eu  
• Australasian Gene and Cell Therapy Society (AGCTS): http://agts.org.au  
• International Society for Stem Cell Research (ISCCR): http://www.isscr.org  
• International Rare Diseases Research Consortium (IRDiRC): http://www.irdirc.org  
• Treat NMD (Europe): http://www.treat-nmd.eu/  
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